|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ricci-Vitiani L, Fabrizi E, Palio E and De
Maria R: Colon cancer stem cells. J Mol Med. 87:1097–1104. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnston PG and Kaye S: Capecitabine: A
novel agent for the treatment of solid tumors. Anticancer Drugs.
12:639–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giacchetti S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y,
Coudert B, et al: Phase III multicenter randomized trial of
oxaliplatin added to chronomodulated fluorouracil-leucovorin as
first-line treatment of metastatic colorectal cancer. J Clin Oncol.
18:136–147. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren D, Wang M, Guo W, Huang S, Wang Z,
Zhao X, Du H, Song L and Peng X: Double-negative feedback loop
between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell
Tissue Res. 358:763–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang
S, Zou X and Peng X: Wild-type p53 suppresses the
epithelial-mesenchymal transition and stemness in PC-3 prostate
cancer cells by modulating miR-145. Int J Oncol. 42:1473–1481.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo W, Ren D, Chen X, Tu X, Huang S, Wang
M, Song L, Zou X and Peng X: HEF1 promotes epithelial mesenchymal
transition and bone invasion in prostate cancer under the
regulation of microRNA-145. J Cell Biochem. 114:1606–1615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Liu J, Zang D, Wu S, Liu A, Zhu
J, Wu G, Li J and Jiang L: Upregulation of miR-572
transcriptionally suppresses SOCS1 and p21 and contributes to human
ovarian cancer progression. Oncotarget. 6:15180–15193.
2015.PubMed/NCBI
|
|
14
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bitarte N, Bandres E, Boni V, Zarate R,
Rodriguez J, Gonzalez-Huarriz M, Lopez I, Sola Javier J, Alonso MM,
Fortes P, et al: MicroRNA-451 is involved in the self-renewal,
tumorigenicity, and chemoresistance of colorectal cancer stem
cells. Stem Cells. 29:1661–1671. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Talmon G and Wang J: MicroRNA-587
antagonizes 5-FU-induced apoptosis and confers drug resistance by
regulating PPP2R1B expression in colorectal cancer. Cell Death Dis.
6:e18452015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martz CA, Ottina KA, Singleton KR, Jasper
JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T,
Alley HM, et al: Systematic identification of signaling pathways
with potential to confer anticancer drug resistance. Sci Signal.
7:ra1212014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yun M, Lee D, Park MN, Kim EO, Sohn EJ,
Kwon BM and Kim SH: Cinnamaldehyde derivative (CB-PIC) sensitizes
chemo-resistant cancer cells to drug-induced apoptosis via
suppression of MDR1 and its upstream STAT3 and AKT signalling. Cell
Physiol Biochem. 35:1821–1830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin A, Yu Q, Gao Y, Tan J, Huang H, Qiao Z
and Qian W: Inhibition of STAT3/cyclinD1 pathway promotes
chemotherapeutic sensitivity of colorectal caner. Biochem Biophys
Res Commun. 457:681–687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin L, Sabnis AJ, Chan E, Olivas V, Cade
L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al: The Hippo
effector YAP promotes resistance to RAF- and MEK-targeted cancer
therapies. Nat Genet. 47:250–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshikawa K, Noguchi K, Nakano Y, Yamamura
M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo
pathway transcriptional co-activator, YAP, confers resistance to
cisplatin in human oral squamous cell carcinoma. Int J Oncol.
46:2364–2370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giovannetti E, Funel N, Peters GJ, Del
Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A,
Falcone A, et al: MicroRNA-21 in pancreatic cancer: Correlation
with clinical outcome and pharmacologic aspects underlying its role
in the modulation of gemcitabine activity. Cancer Res.
70:4528–4538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hwang JH, Voortman J, Giovannetti E,
Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH,
et al: Identification of microRNA-21 as a biomarker for
chemoresistance and clinical outcome following adjuvant therapy in
resectable pancreatic cancer. PLoS One. 5:e106302010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang M, Ren D, Guo W, Huang S, Wang Z, Li
Q, Du H, Song L and Peng X: N-cadherin promotes
epithelial-mesenchymal transition and cancer stem cell-like traits
via ErbB signaling in prostate cancer cells. Int J Oncol.
48:595–606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hahn WC, Dessain SK, Brooks MW, King JE,
Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration
of the simian virus 40 early region elements necessary for human
cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Ren D, Guo L, Wang L, Wu S, Lin
C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key
regulator of tumorigenesis and metastasis and a novel serum marker
in breast cancer. Breast Cancer Res. 19:152017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Chen Y, Hao L, Hou A, Chen X, Li
Y, Wang R, Luo P, Ruan Z, Ou J, et al: Macrophages induce
resistance to 5-fluorouracil chemotherapy in colorectal cancer
through the release of putrescine. Cancer Lett. 381:305–313. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Liu F, Lin B, Luo H, Liu M, Wu J, Li
C, Li R, Zhang X, Zhou K, et al: miR-150 inhibits proliferation and
tumorigenicity via retarding G1/S phase transition in
nasopharyngeal carcinoma. Int J Oncol. Mar 10–2017.(Epub ahead of
print). doi: 10.3892/ijo.2017.3909.
|
|
31
|
Tan G, Cao X, Dai Q, Zhang B, Huang J,
Xiong S, Zhang Y, Chen W, Yang J and Li H: A novel role for
microRNA-129-5p in inhibiting ovarian cancer cell proliferation and
survival via direct suppression of transcriptional co-activators
YAP and TAZ. Oncotarget. 6:8676–8686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hall CA, Wang R, Miao J, Oliva E, Shen X,
Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway
effector Yap is an ovarian cancer oncogene. Cancer Res.
70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo PD, Lu XX, Gan WJ, Li XM, He XS, Zhang
S, Ji QH, Zhou F, Cao Y, Wang JR, et al: RARγ downregulation
contributes to colorectal tumorigenesis and metastasis by
derepressing the Hippo-Yap pathway. Cancer Res. 76:3813–3825. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chan SW, Lim CJ, Loo LS, Chong YF, Huang C
and Hong W: TEADs mediate nuclear retention of TAZ to promote
oncogenic transformation. J Biol Chem. 284:14347–14358. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du C, Huang D, Peng Y, Yao Y, Zhao Y, Yang
Y, Wang H, Cao L, Zhu WG and Gu J: 5-Fluorouracil targets histone
acetyltransferases p300/CBP in the treatment of colorectal cancer.
Cancer Lett. 400:183–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dan I, Watanabe NM and Kusumi A: The Ste20
group kinases as regulators of MAP kinase cascades. Trends Cell
Biol. 11:220–230. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yu FX and Guan KL: The Hippo pathway:
Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu CY, Zha ZY, Zhou X, Zhang H, Huang W,
Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al: The hippo tumor
pathway promotes TAZ degradation by phosphorylating a phosphodegron
and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem.
285:37159–37169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiang L, Gilkes DM, Hu H, Takano N, Luo W,
Lu H, Bullen JW, Samanta D, Liang H and Semenza GL:
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear
localization to induce the breast cancer stem cell phenotype.
Oncotarget. 5:12509–12527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
45
|
Huang J, Wu S, Barrera J, Matthews K and
Pan D: The Hippo signaling pathway coordinately regulates cell
proliferation and apoptosis by inactivating Yorkie, the
Drosophila homolog of YAP. Cell. 122:421–434. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F,
Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is
inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS
and Yang X: TAZ is a novel oncogene in non-small cell lung cancer.
Oncogene. 30:2181–2186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lee KP, Lee JH, Kim TS, Kim TH, Park HD,
Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, et al: The
Hippo-Salvador pathway restrains hepatic oval cell proliferation,
liver size, and liver tumorigenesis. Proc Natl Acad Sci USA.
107:8248–8253. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou D, Zhang Y, Wu H, Barry E, Yin Y,
Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, et al:
Mst1 and Mst2 protein kinases restrain intestinal stem cell
proliferation and colonic tumorigenesis by inhibition of
Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA.
108:E1312–E1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Reddy BV and Irvine KD: Regulation of
Hippo signaling by EGFR-MAPK signaling through Ajuba family
proteins. Dev Cell. 24:459–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fan R, Kim NG and Gumbiner BM: Regulation
of Hippo pathway by mitogenic growth factors via phosphoinositide
3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad
Sci USA. 110:2569–2574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian
AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, et al:
LIFR is a breast cancer metastasis suppressor upstream of the
Hippo-YAP pathway and a prognostic marker. Nat Med. 18:1511–1517.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang Y and Lai ZC: Mob as tumor
suppressor is regulated by bantam microRNA through a feedback loop
for tissue growth control. Biochem Biophys Res Commun. 439:438–442.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lin CW, Chang YL, Chang YC, Lin JC, Chen
CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM, et al: MicroRNA-135b
promotes lung cancer metastasis by regulating multiple targets in
the Hippo pathway and LZTS1. Nat Commun. 4:18772013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen M, Wang M, Xu S, Guo X and Jiang J:
Upregulation of miR-181c contributes to chemoresistance in
pancreatic cancer by inactivating the Hippo signaling pathway.
Oncotarget. 6:44466–44479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Allen KE and Weiss GJ: Resistance may not
be futile: MicroRNA biomarkers for chemoresistance and potential
therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gisel A, Valvano M, El Idrissi IG,
Nardulli P, Azzariti A, Carrieri A, Contino M and Colabufo NA:
miRNAs for the detection of multidrug resistance: Overview and
perspectives. Molecules. 19:5611–5623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yin Y, Zhang B, Wang W, Fei B, Quan C,
Zhang J, Song M, Bian Z, Wang Q, Ni S, et al: miR-204-5p inhibits
proliferation and invasion and enhances chemotherapeutic
sensitivity of colorectal cancer cells by downregulating RAB22A.
Clin Cancer Res. 20:6187–6199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhao Y and Yang X: The Hippo pathway in
chemotherapeutic drug resistance. Int J Cancer. 137:2767–2773.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Fujimoto D, Ueda Y, Hirono Y, Goi T and
Yamaguchi A: PAR1 participates in the ability of multidrug
resistance and tumorigenesis by controlling Hippo-YAP pathway.
Oncotarget. 6:34788–34799. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Su Z, Zhi X, Zhang Q, Yang L, Xu H and Xu
Z: LncRNA H19 functions as a competing endogenous RNA to regulate
AQP3 expression by sponging miR-874 in the intestinal barrier. FEBS
Lett. 590:1354–1364. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kushwaha P, Khedgikar V, Sharma D, Yuen T,
Gautam J, Ahmad N, Karvande A, Mishra PR, Trivedi PK, Sun L, et al:
MicroRNA 874-3p exerts skeletal anabolic effects epigenetically
during weaning by suppressing Hdac1 expression. J Biol Chem.
291:3959–3966. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wu G, Yang G, Zhang R, Xu G, Zhang L, Wen
W, Lu J, Liu J and Yu Y: Altered microRNA expression profiles of
extracellular vesicles in nasal mucus from patients with allergic
rhinitis. Allergy Asthma Immunol Res. 7:449–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Colangelo V, François S, Soldà G, Picco R,
Roma F, Ginelli E and Meneveri R: Next-generation sequencing
analysis of miRNA expression in control and FSHD myogenesis. PLoS
One. 9:e1084112014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Suojalehto H, Lindström I, Majuri ML,
Mitts C, Karjalainen J, Wolff H and Alenius H: Altered microRNA
expression of nasal mucosa in long-term asthma and allergic
rhinitis. Int Arch Allergy Immunol. 163:168–178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sheinerman KS, Tsivinsky VG, Abdullah L,
Crawford F and Umansky SR: Plasma microRNA biomarkers for detection
of mild cognitive impairment: Biomarker validation study. Aging.
5:925–938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sheinerman KS, Tsivinsky VG, Crawford F,
Mullan MJ, Abdullah L and Umansky SR: Plasma microRNA biomarkers
for detection of mild cognitive impairment. Aging. 4:590–605. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang LQ, Sun SL, Li WY, Feng Z, Xu XY,
Zhuang QS and Fang J: Decreased expression of tumor suppressive
miR-874 and its clinical significance in human osteosarcoma. Genet
Mol Res. 14:18315–18324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Dong D, Gong Y, Zhang D, Bao H and Gu G:
miR-874 suppresses the proliferation and metastasis of osteosarcoma
by targeting E2F3. Tumour Biol. 37:6447–6455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fisher JN, Terao M, Fratelli M, Kurosaki
M, Paroni G, Zanetti A, Gianni M, Bolis M, Lupi M, Tsykin A, et al:
MicroRNA networks regulated by all-trans retinoic acid and
Lapatinib control the growth, survival and motility of breast
cancer cells. Oncotarget. 6:13176–13200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li
Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 functions as a tumor
suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway
in gastric cancer. Oncotarget. 6:1605–1617. 2015.PubMed/NCBI
|
|
73
|
Wang L, Gao W, Hu F, Xu Z and Wang F:
MicroRNA-874 inhibits cell proliferation and induces apoptosis in
human breast cancer by targeting CDK9. FEBS Lett. 588:4527–4535.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Jiang B, Li Z, Zhang W, Wang H, Zhi X,
Feng J, Chen Z, Zhu Y, Yang L, Xu H, et al: miR-874 inhibits cell
proliferation, migration and invasion through targeting aquaporin-3
in gastric cancer. J Gastroenterol. 49:1011–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kesanakurti D, Maddirela DR, Chittivelu S,
Rao JS and Chetty C: Suppression of tumor cell invasiveness and in
vivo tumor growth by microRNA-874 in non-small cell lung cancer.
Biochem Biophys Res Commun. 434:627–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nohata N, Hanazawa T, Kinoshita T, Inamine
A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto
Y, et al: Tumour-suppressive microRNA-874 contributes to cell
proliferation through targeting of histone deacetylase 1 in head
and neck squamous cell carcinoma. Br J Cancer. 108:1648–1658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Han J, Liu Z, Wang N and Pan W:
MicroRNA-874 inhibits growth, induces apoptosis and reverses
chemoresistance in colorectal cancer by targeting X-linked
inhibitor of apoptosis protein. Oncol Rep. 36:542–550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang XJ, Xia M and Bi WP: Decreased
expression of miR-874 and its tumor suppressive function in human
colorectal cancer. Genet Mol Res. 15:150280772016.
|
|
79
|
Zhao B and Dong AS: MiR-874 inhibits cell
growth and induces apoptosis by targeting STAT3 in human colorectal
cancer cells. Eur Rev Med Pharmacol Sci. 20:269–277.
2016.PubMed/NCBI
|
